Gerda Elisabeth Villadsen

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Sergio Muñoz-Martínez, University of Barcelona
  • ,
  • Victor Sapena, University of Barcelona
  • ,
  • Alejandro Forner, University of Barcelona
  • ,
  • Jean Charles Nault, Hopital Avicenne, Universite Paris 13, Sorbonne Université
  • ,
  • Gonzalo Sapisochin, University of Toronto
  • ,
  • Lorenza Rimassa, IRCCS Istituto Clinico Humanitas - Rozzano (Milano), Humanitas University
  • ,
  • Bruno Sangro, University of Navarra
  • ,
  • Jordi Bruix, University of Barcelona
  • ,
  • Marco Sanduzzi-Zamparelli, University of Barcelona
  • ,
  • Wacław Hołówko, Medical University of Warsaw
  • ,
  • Mohamed El Kassas, Helwan University
  • ,
  • Tudor Mocan, Iuliu Hatieganu University of Medicine and Pharmacy
  • ,
  • Mohamed Bouattour, Hopital Beaujon
  • ,
  • Philippe Merle, Groupement Hospitalier Lyon Nord
  • ,
  • Frederik J.H. Hoogwater, University of Groningen
  • ,
  • Saleh A. Alqahtani, Alfaisal University
  • ,
  • Helen L. Reeves, Newcastle upon Tyne Hospitals NHS Foundation Trust
  • ,
  • David J. Pinato, Imperial College London
  • ,
  • Emmanouil Giorgakis, University of Arkansas for Medical Sciences
  • ,
  • Tim Meyer, University College London
  • ,
  • Gerda Elisabeth Villadsen
  • Henning Wege, University of Hamburg
  • ,
  • Massimiliano Salati, University of Modena and Reggio Emilia
  • ,
  • Beatriz Mínguez, Autonomous University of Barcelona
  • ,
  • Giovan Giuseppe Di Costanzo, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
  • ,
  • Christoph Roderburg, Charité – Universitätsmedizin Berlin
  • ,
  • Frank Tacke, Charité – Universitätsmedizin Berlin
  • ,
  • María Varela, University of Oviedo
  • ,
  • Peter R. Galle, Johannes Gutenberg University Mainz
  • ,
  • Mario Reis Alvares-da-Silva, Universidade Federal do Rio Grande do Sul
  • ,
  • Jörg Trojan, Goethe University Frankfurt
  • ,
  • John Bridgewater, University College London
  • ,
  • Giuseppe Cabibbo, University of Palermo
  • ,
  • Christian Toso, University of Geneva
  • ,
  • Anja Lachenmayer, University of Bern
  • ,
  • Andrea Casadei-Gardini, University of Modena and Reggio Emilia
  • ,
  • Hidenori Toyoda, Ogaki Municipal Hospital
  • ,
  • Tom Lüdde, Heinrich Heine University Düsseldorf
  • ,
  • Rosanna Villani, University of Foggia
  • ,
  • Ana María Matilla Peña, CIBER - Center for Biomedical Research Network
  • ,
  • Cassia Regina Guedes Leal, Hospital Federal dos Servidores do Estado
  • ,
  • Monica Ronzoni, Vita-Salute San Raffaele University
  • ,
  • Manuel Delgado, Hospital Juan Canalejo
  • ,
  • Christie Perelló, University Hospital Puerta de Hierro
  • ,
  • Sonia Pascual, CIBER - Center for Biomedical Research Network
  • ,
  • José Luis Lledó, Hospital Ramon y Cajal
  • ,
  • Josepmaria Argemi, University of Navarra
  • ,
  • Bristi Basu, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust
  • ,
  • Leonardo da Fonseca, Universidade de Sao Paulo
  • ,
  • Juan Acevedo, University Hospitals Plymouth NHS Trust
  • ,
  • Alexander R. Siebenhüner, University of Zurich
  • ,
  • Chiara Braconi, University of Glasgow
  • ,
  • Brandon M. Meyers, McMaster University
  • ,
  • Alessandro Granito, S. Orsola-Malpighi Polyclinic
  • ,
  • Margarita Sala, CIBER - Center for Biomedical Research Network
  • ,
  • Carlos Rodríguez-Lope, Hospital Universitario Marques de Valdecilla
  • ,
  • Lorraine Blaise, Hopital Avicenne, Universite Paris 13, Sorbonne Université
  • ,
  • Manuel Romero-Gómez, CIBER - Center for Biomedical Research Network
  • ,
  • Federico Piñero, Universidad Austral
  • ,
  • Dhanny Gomez, Nottingham University Hospitals NHS Trust
  • ,
  • Vivianne Mello, AMO Clinic
  • ,
  • Rogerio Camargo Pinheiro Alves, Hospital do Servidor Publico Estadual
  • ,
  • Alex França, Universidade Federal de Sergipe
  • ,
  • Fernanda Branco, CliniOnco
  • ,
  • Giovanni Brandi, S. Orsola-Malpighi Polyclinic
  • ,
  • Gustavo Pereira, Hospital Federal de Bonsucesso
  • ,
  • Susanna Coll, Pompeu Fabra University
  • ,
  • Maria Guarino, University of Naples Federico II
  • ,
  • Carlos Benítez, Pontificia Universidad Catolica de Chile
  • ,
  • Maria Margarita Anders, Hospital Alemán
  • ,
  • Juan C. Bandi, Hospital Italiano de Buenos Aires
  • ,
  • Mercedes Vergara, Autonomous University of Barcelona, CIBER - Center for Biomedical Research Network
  • ,
  • Mariona Calvo, Institute Catala Oncologia
  • ,
  • Markus Peck-Radosavljevic, Klinikum Klagenfurt am Wörthersee
  • ,
  • Ignacio García-Juárez, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  • ,
  • Vincenzo Cardinale, University of Rome La Sapienza
  • ,
  • Mar Lozano, Complutense University of Madrid
  • ,
  • Martina Gambato, Azienda Ospedaliera di Padova
  • ,
  • Stefano Okolicsanyi, Umberto Parini Hospital
  • ,
  • Dalia Morales-Arraez, Hospital Universitario de Canarias
  • ,
  • Alessandra Elvevi, Azienda Ospedaliera San Gerardo Monza
  • ,
  • Alberto E. Muñoz, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo
  • ,
  • Alberto Lué, Hospital San Jorge
  • ,
  • Massimo Iavarone, IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano
  • ,
  • Maria Reig, University of Barcelona

Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

Original languageEnglish
Article number100260
JournalJHEP Reports
Volume3
Issue3
Number of pages9
ISSN2589-5559
DOIs
Publication statusPublished - Jun 2021

    Research areas

  • Cholangiocarcinoma, Clinical trials, COVID-19, Hepatocellular carcinoma, Liver cancer, Management, Nurses

See relations at Aarhus University Citationformats

ID: 225230325